

## Special Issue

# Immune Checkpoint Inhibitor in Cancer Therapy: Recent Advances

### Message from the Guest Editor

The treatment landscape for many cancers is rapidly evolving with the advent of immune checkpoint inhibitors and multi-omics. Combining the insights of next-generation sequencing along with transcriptomic and immunomic data can often inform treatment decision making for some cancers. In certain circumstances the use of immune checkpoint inhibitors has led to dramatic responses in various tumor types. Understanding which patients may yield the most benefit from these agents, and deciphering how to hijack this response for patients who do not have such responses are important and of interest. Various groups have led and continue to lead efforts into combining immune checkpoint in combination with various targeted therapies in efforts to improve responses to these agents. Additionally, there is an abundance of ongoing clinical trials to investigate novel checkpoints. In this Special Issue, we aim to draw together research from experts in the field that highlight immunotherapeutic agents and strategies, and identify future directions that will lead to discoveries and therapies for these drugs in patients with cancer.

---

### Guest Editor

Dr. Jacob J Adashek

The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, MD, USA

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/129693](https://mdpi.com/si/129693)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)